£
Donate
Donate

In this project, Dr Calado will try and understand more about why some types of DLBCL stop responding to treatment.

Project information

Lead researcher

Dr Dinis Calado, Francis Crick Institute

Research team
  • A team at Francis Crick Institute
Related conditions
  • Diffuse large B-cell lymphoma (DLBCL)
Research type
  • Non-clinical
Region
  • London
Grant awarded
  • Project Grant
Status
Ongoing
Funding award date
June 2023
Amount awarded

£250,000

The challenge

Diffuse large B cell lymphoma (DLBCL) is an aggressive type of lymphoma that can be treated, but some people have lymphoma that doesn’t respond well to therapy which means they see their cancer return. We need to understand how some types of DLBCL resist treatment.

The project

There are certain features of some types of DLBCL that are known to make the disease less likely to respond to treatment, but this is very difficult to study and difficult to test people for.

In this project, Dr Calado and his team want to create a new model of the disease so they can understand more about how certain lymphomas resist treatment and how we might predict this. They then want to see if they can find ways to stop this from happening.

There is a real unmet need for research on cancers that are resistant to existing treatments. The type of blood cancer being studied in this project is amongst the most difficult to treat.

- Patient Voice Grant Advisory Network Member, in remission from non-Hodgkin lymphoma

The future

The hope is that this work could lead to new treatments being developed for DLBCL to try and reduce the chance of relapse in the most aggressive types of the disease.

Help us beat blood cancer by funding a research project

  • Could help eight people newly diagnosed with blood cancer understand their condition.
  • Could help researchers study blood cancer cells to develop new treatments and improve early diagnosis.
  • Could help scientists identify genetic patterns in tumour samples to better understand how genes contribute to the development of blood cancer.
Donate